nach oben

Medical Oncology

Erschienen in:

01.01.2014 | Original Paper

The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis

verfasst von: Xiaojun Li, Chunyan Yang, Xiaoqiang Wang, Jian Zhang, Ruipeng Zhang, Ruiting Liu

Erschienen in: Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

MicroRNA-25 (miR-25) has recently been found to be involved in many critical processes in human malignancies. We aimed to investigate the expression pattern and prognostic role of miR-25 in colorectal cancer. Colorectal cancer and adjacent normal specimens from 186 patients who had not received neoadjuvant chemotherapy were collected. The expression of miR-25 was detected with a quantitative real-time PCR assay, and the association of miR-25 with overall patient survival was analyzed via statistical analysis. The results indicated that the level of miR-25 expression was significantly elevated in colorectal cancer compared with the level observed in the adjacent normal tissue. It was also demonstrated that miR-25 expression is associated with tumor invasion, lymph node metastasis, distant metastasis and the TNM stage of colorectal cancer. In addition, a Kaplan–Meier analysis revealed that an increased level of miR-25 expression is associated with a poor overall survival of patients. A multivariate survival analysis also indicated that miR-25 is an independent prognostic marker after adjusting for known prognostic factors. These results prove that miR-25 expression is increased in colorectal cancer and is associated with tumor progression. This study also provides the first evidence that miR-25 is an independent prognostic factor for patients with colorectal cancer, indicating the potential role of miR-25 as a highly specific and sensitive biomarker.

Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.20138.PubMedCrossRef

Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366–78. doi:10.3322/caac.20038.PubMedCrossRef

Deng SX, An W, Gao J, Yin J, Cai QC, Yang M, et al. Factors influencing diagnosis of colorectal cancer: a hospital-based survey in China. J Dig Dis. 2012;13(10):517–24. doi:10.1111/j.1751-2980.2012.00626.x.PubMedCrossRef

Chen HM, Weng YR, Jiang B, Sheng JQ, Zheng P, Yu CG, et al. Epidemiological study of colorectal adenoma and cancer in symptomatic patients in China between 1990 and 2009. J Dig Dis. 2011;12(5):371–8. doi:10.1111/j.1751-2980.2011.00531.x.PubMedCrossRef

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41. doi:10.3322/caac.21149.PubMedCrossRef

Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57(3):168–85.PubMedCrossRef

Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3(3):83–92.PubMedCentralPubMed

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33. doi:10.1016/j.cell.2009.01.002.PubMedCentralPubMedCrossRef

John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol. 2004;2(11):e363. doi:10.1371/journal.pbio.0020363.PubMedCentralPubMedCrossRef

10.

Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, et al. A combined computational-experimental approach predicts human microRNA targets. Genes Dev. 2004;18(10):1165–78. doi:10.1101/gad.1184704.PubMedCrossRef

11.

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66. doi:10.1038/nrc1997.PubMedCrossRef

12.

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103(7):2257–61. doi:10.1073/pnas.0510565103.PubMedCrossRef

13.

Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012;12:505. doi:10.1186/1471-2407-12-505.PubMedCentralPubMedCrossRef

14.

Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol WJG. 2009;15(17):2089–96.CrossRef

15.

Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29. doi:10.1186/1476-4598-5-29.PubMedCentralPubMedCrossRef

16.

Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34(4):1069–75.PubMed

17.

Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, et al. microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 2012;33(1):220–5. doi:10.1093/carcin/bgr245.PubMedCrossRef

18.

Liu L, Chen L, Xu Y, Li R, Du X. microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 2010;400(2):236–40. doi:10.1016/j.bbrc.2010.08.046.PubMedCrossRef

19.

Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. Identification of the miR-106b ~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010;3(117):ra29. doi:10.1126/scisignal.2000594.PubMedCentralPubMedCrossRef

20.

Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK. Survey of MicroRNA expression in pediatric brain tumors. Pediatr Blood Cancer. 2011;56(2):211–6. doi:10.1002/pbc.22723.PubMedCrossRef

21.

Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13(3):272–86. doi:10.1016/j.ccr.2008.02.013.PubMedCrossRef

22.

Dacic S, Kelly L, Shuai Y, Nikiforova MN. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol. 2010;23(12):1577–82. doi:10.1038/modpathol.2010.152.PubMedCrossRef

23.

Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 2009;100(7):1234–42. doi:10.1111/j.1349-7006.2009.01164.x.PubMedCrossRef

24.

Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74. doi:10.1038/nrg3074.PubMedCrossRef

25.

He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31. doi:10.1038/nrg1379.PubMedCrossRef

26.

Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005;4(9):1179–84.PubMedCrossRef

27.

Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer. 2011;11(12):849–64. doi:10.1038/nrc3166.PubMedCrossRef

28.

Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res. 2007;619(1–2):30–7. doi:10.1016/j.mrfmmm.2006.12.006.PubMedCrossRef

29.

Zhao H, Wang Y, Yang L, Jiang R, Li W. miR-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 2013;. doi:10.1007/s11010-013-1829-x.

30.

Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27(2):594–8. doi:10.3892/or 2011.1530.PubMed

31.

Xu JY, Yang LL, Ma C, Huang YL, Zhu GX, Chen QL. MiR-25-3p attenuates the proliferation of tongue squamous cell carcinoma cell line Tca8113. Asian Pac J Trop Biomed. 2013;6(9):743–7. doi:10.1016/S1995-7645(13)60130-3.

32.

Wang Y, Li Z, He C, Wang D, Yuan X, Chen J, et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis. 2010;44(3):191–7. doi:10.1016/j.bcmd.2009.12.010.PubMedCentralPubMedCrossRef

33.

Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang Z, et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2012;421(4):640–5. doi:10.1016/j.bbrc.2012.03.048.PubMedCrossRef

Titel: The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis
verfasst von: Xiaojun Li
Chunyan Yang
Xiaoqiang Wang
Jian Zhang
Ruipeng Zhang
Ruiting Liu
Publikationsdatum: 01.01.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 1/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-013-0781-7

Springer Medizin

The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors

Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma

Hibernomas: a single-institution experience and review of literature

Elevated expression patterns and tight correlation of the PLCE1 and NF-κB signaling in Kazakh patients with esophageal carcinoma

Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer

Hodgkin lymphoma transformation of chronic lymphocytic leukemia: cases report and discussion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie